| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Emily Bodnar reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $36 price ta...
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(...
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small mole...